Here's why I added Resmed shares to my portfolio last week

Fear is consuming the Resmed share price. I've decided to take action while the market is panicking.

| More on:
A man sleeps in a bed with white sheets while holding a teddy bear and a smile on his face.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In less than two months, Resmed Inc (ASX: RMD) shares have cascaded 35.7% to their lowest price since March 2020.

The violent hit to the medical device company comes amid mounting fears of market disruption caused by glucagon-like peptide 1 (GLP-1) drugs.

Going against the grain, I decided to buy Resmed shares last week. In this article, I'll explain why I think the market is being irrational and how Resmed could still succeed in this evolving landscape.

Shoot first, ask questions later

Known more commonly by their label names, such as Wegovy and Mounjaro, weight-loss medications are creating a ruckus in the healthcare industry. The fear is that GLP-1s could uproot existing indirect treatments due to the prevalent link between an array of health issues and obesity.

It's a classic example of root cause analysis: addressing the source of the problem rather than trying to treat the symptoms.

Resmed is a big player in treating obstructive sleep apnea (OSA) — a sleep disorder believed to affect 20% of the global population. It is commonly cited that obesity is considered one of the main risk factors for sleep apnea, with estimates indicating roughly 70% of OSA sufferers are obese.

Investors are worried that these new medications could usurp Resmed by solving the underlying cause of the disorder it treats, hurting Resmed shares. While the jury is still out on the substantive evidence, it appears shareholders are not waiting around to find out.

Three reasons why I think GLP-1s won't eat Resmed's lunch

I want to provide three clear-cut points for why I added Resmed to my portfolio.

  1. Early evidence for reduced sleep apnea from GLP-1 use is combined with exercise and a restrictive diet. This may suggest that sleep apnea issues could persist without lifestyle changes.
  2. If GLP-1s do disrupt the OSA industry, the market opportunity remains significant. An estimated ~485 million people with sleep apnea are not exposed to obesity — Resmed currently serves around 160 million.
  3. Weight-loss medications and continuous positive airway pressure machines (CPAP) — the devices Resmed sells — could be complementary.

Homing in on that last point. The real winners from this are the people who suffer from sleep apnea. It may give people more choice. Studies show that some people don't stick with CPAP machines… likewise, others don't gel with these new medications.

I think investors are forgetting that different solutions can co-exist in large markets.

Pulling the trigger on Resmed shares

I have long admired Resmed as a company. The ability to constantly innovate on its devices, expand its market share, and maintain commendable margins.

However, during my time as an investor, the Resmed shares price has usually traded on a price-to-earnings (P/E) ratio of between 30 and 50 times. I couldn't stomach the premium price. A mistake in hindsight.

The market's recent irrationality, in my opinion, has given me a second chance. Now, Resmed trades at 24 times earnings.

Still conscious of the risks, I have added a modest position with the intention to add more in the future. Right now, Resmed shares make up 2.7% of my personal portfolio.

Motley Fool contributor Mitchell Lawler has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer

These 2 ASX 200 shares just hit 52-week lows: I rate them as buys

These two stocks look too cheap to miss!

Read more »

A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop

Could CSL stock be a millionaire-maker at $261

Does the exceptional biotech company still harness the power to make an investment today worth a million in the future?

Read more »

Three women athletes lie flat on a running track as though they have had a long hard race where they have fought hard but lost the event.
Cheap Shares

3 of the best ASX shares to buy before they start to recover

The ASX 200 has dived since reporting season, so there are bargains to be picked up right now.

Read more »

A mature aged man with grey hair and glasses holds a fan of Australian hundred dollar bills up against his mouth and looks skywards with his eyes as though he is thinking what he might do with the cash.

Where to invest $6,500 in November 2023

I think it's a great time to start putting money to work.

Read more »

An older couple use a calculator to work out what money they have to spend.
Dividend Investing

Retirees: 2 high-yield ASX dividend shares to buy for passive income

Income investors have to be careful to not lose 40% of capital while raking in 20% yield.

Read more »

Copal miner standing in front of coal.
Dividend Investing

Should you buy New Hope stock for its 10% dividend yield?

These shares look cheap right now. But will they sink even further from here or are there brighter days ahead?

Read more »

Woman with $50 notes in her hand thinking, symbolising dividends.

The top ASX shares I'd buy with $500 right now

I think putting $500 into any of these ASX shares today would be a great move.

Read more »


School-leaver to retiree: ASX stocks I'd buy for each age bracket

If life is a journey, here are the stocks I'd pick up along the way.

Read more »